cas 90213-66-4|| where to buy 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine

Produktname:2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine

IUPAC Name:2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM103618-100g	in stock	ȯǑ
CM103618-500g	in stock	ȖȖȅ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 90213-66-4 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:90213-66-4; Molekulare Formel:C6H3Cl2N3; Schmelzpunkt:-; SMILES-Code:ClC1=NC(Cl)=C2C=CNC2=N1; Dichte:

: Katalognummer:CM103618; Molekulargewicht:188.01; Siedepunkt:; Mdl-Nr.:MFCD08059278; Lagerung:-20°C

: Pyrrolopyrimidines; Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.

: Capivasertib; On November 16, FDA approved Capivasertib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative locally advanced or metastatic breast cancer. Capivasertib is a highly selective inhibitor targeting three AKT subtypes (AKT1/2/3), which can block signals used by cancer cells for division and growth.